Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.



We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.



To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.

COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
17,669
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 313 571 17,764
          North America 71 112 11,221
          Europe 127 179 3,530
          Asia Pacific 38 90 571
          Latin America 55 144 1,253
          SWAAC 22 46 1,189
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Year To Date

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
598
COVID-19
In-hospital Mortality
34%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 598 199
Age(years)
Median(IQR) 9(1,16) 13(2,17)
# observed 598 199
BMI, kg/m2
Median(IQR) 22(16,35) 31(21,40)
# observed 512 179
Sex
Male 51%(304) 52%(103)
Female 49%(294) 48%(96)
# observed 598 199
Race/Ethnicity
Black 20%(118) 18%(35)
White (Non-Hispanic) 37%(222) 38%(76)
Asian 5%(28) 4%(8)
Mid East, N African 3%(19) 4%(8)
Other 3%(15) 3%(5)
Unknown 5%(27) 5%(10)
Multiple 4%(24) 4%(8)
Hispanic 24%(145) 25%(49)
# observed 598 199
Pre-ECMO Comorbidities
No comorbidity 47%(281) 35%(69)
Cancer 4%(21) 4%(7)
Pregnancy 1%(3) 1%(2)
Immunocompromised 8%(49) 9%(17)
Diabetes 7%(41) 11%(21)
Pre-existing heart disease 7%(41) 2%(3)
Pre-existing lung disease 6%(33) 7%(13)
Pre-existing renal insuff. 2%(10) 1%(2)
Frailty 2%(13) 1%(2)
Asthma 12%(73) 18%(36)
BMI $> 30 \mathrm{kg}/\mathrm{m}^2$ 26%(157) 44%(88)
Hypertension 5%(31) 11%(21)
# observed 598 199
Acute illness
ARDS 51%(304) 100%(199)
Acute heart failure 21%(124) 5%(9)
Myocarditis 14%(82) 1%(2)
Acute kidney injury 20%(117) 19%(37)
# observed 598 199
Pre-ECMO Cardiac Arrest
Yes 23%(140) 8%(15)
No 77%(456) 92%(184)
# observed 596 199
Pre-ECMO Co-Infection
No Co-infection 52%(312) 45%(90)
Bacterial pneumonia 32%(191) 44%(87)
Co-viral infection 22%(133) 21%(41)
Blood stream infection 14%(84) 18%(36)
Urinary tract infection 5%(29) 10%(19)
# observed 598 199

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 598 199
Noninvasive ventilation
Noninvasive ventilation prior to intubation 65%(388) 84%(168)
BiPAP 31%(188) 49%(97)
CPAP 10%(60) 13%(26)
HFNC 44%(261) 55%(110)
# observed 598 199
Pre-ECLS intubation (days)
Median(IQR) 0.7(0.2,3.2) 1.5(0.3,4.6)
# observed 510 177
Ventilator mode
Conventional 81%(419) 82%(147)
# observed 515 180
PEEP, cm H2O
Median(IQR) 10.0(8.0,14.0) 14.0(10.0,16.0)
# observed 394 139
PIP, cm H2O
Median(IQR) 31.0(24.0,37.0) 35.0(29.0,39.0)
# observed 360 125
FiO2
Median(IQR) 1.00(0.90,1.00) 1.00(0.96,1.00)
# observed 472 170
PaO2/FiO2
Median(IQR) 68(54,123) 65(54,94)
# observed 452 164
PCO2
Median(IQR) 54(42,69) 60(49,71)
# observed 487 173
Pre-ECMO Support
Prone positioning 17%(101) 33%(66)
# observed 597 199
Neuromuscular blockers 64%(385) 75%(149)
# observed 597 199
Inhaled pulmonary vasodilators 32%(193) 43%(86)
# observed 597 199
Any vasoactive support 64%(383) 55%(110)
# observed 597 199
Norepinephrine 32%(192) 32%(64)
# observed 597 199
Therapies, Immunomodulators
Any therapy 80%(480) 90%(179)
Glucocorticoids 70%(421) 83%(165)
IVIG 19%(115) 8%(15)
Anti-cytokine 21%(127) 24%(47)
Lopinavir/Ritonavir 1%(4) 2%(3)
JAK inhibition 2%(11) 3%(6)
Chloroquine/hydroxychloroquine 2%(12) 4%(7)
Remdesivir 48%(288) 56%(111)
# observed 598 199
Support type
Respiratory 65%(390) 99%(198)
Cardiac 26%(154) 0%(0)
ECPR 9%(54) 1%(1)
# observed 598 199

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 47%(283) 49%(97)
Discharged alive to long-term acute care or unspecified location 7%(43) 10%(19)
Discharged to another hospital 10%(60) 12%(23)
Remain in the hospital (discharged from ICU) 0%(0) 0%(0)
Remain in the ICU 0%(2) 0%(0)
In-hospital death 35%(210) 30%(60)
Tracheostomy 17%(99) 31%(58)
# observed 572 190
Select complications
Seizures 3%(16) 1%(2)
# observed 598 199
CNS infarction by US/CT/MRI 5%(29) 1%(1)
# observed 598 199
CNS hemorrhage by US/CT/MRI 4%(26) 3%(6)
# observed 598 199
Hemolysis 10%(61) 12%(24)
# observed 598 199
Oxygenator failure 10%(58) 16%(31)
# observed 598 199
Pump failure 1%(8) 1%(2)
# observed 598 199
Circuit change 11%(65) 14%(27)
# observed 598 199
Thrombosis/Clots in circuit component 5%(29) 7%(14)
# observed 598 199
Discharge location
Home 59%(228) 52%(72)
Transfer to LTAC or Rehab
Transfer to another hospital 16%(60) 17%(23)
Other/Unknown 6%(23) 6%(8)
*N/A - Data elements with n<5 are not displayed.